EXTRACELLULAR HEAT SHOCK PROTEIN 60 AS A POTENTIAL BIOMARKER OF ACUTE MYOCARDIAL INFARCTION

The growing burden of cardiovascular diseases necessitates the search for new predictive biomarkers for more accurate diagnosis and prognosis of cardiovascular diseases. Thus, our study aimed to quantify circulating HSP60 levels in serum of acute myocardial infarction patients versus controls and assess its diagnostic value. Materials and Methods. The study enrolled 34 patients with confirmed acute myocardial infarction Materials and Methods. The study included 34 patients with verified acute myocardial infarction and 20 conditionally healthy individuals matched for sex and age. The concentration of HSP60 in the serum was determined by enzyme-linked immunosorbent assay, statistical processing was performed using the specialized StatTech software. Results. The HSP60 level in the AMI group (2.40 ± 0.75 ng/ml) was statistically significantly higher than in the control (0.52 ± 0.25 ng/ml; p < 0.001). ROC analysis revealed a high diagnostic value of HSP60 (AUC = 0.92; p < 0.001). The cutoff value of 1.2 ng/ml provided a sensitivity of 91% and a specificity of 85% for predicting acute myocardial infarction. A strong positive correlation was established between HSP60 and the level of high-sensitivity troponin, as well as with markers of systemic inflammation. A strong direct correlation was found between HSP60 and HSP70 (r = 0.82; p = 0.002). Higher HSP60 levels (≥2 ng/ml) were noted in patients with comorbid cerebral atherosclerosis. No significant correlation was found between HSP60 and standard markers of heart failure (SCF, NT-proBNP). The HSP60 level did not depend on age, gender, and traditional risk factors. Thus, circulating HSP60 can be considered a promising biomarker with high sensitivity and specificity, reflecting systemic inflammatory activity and independent of traditional risk factors. Further study of HSP60 offers potential for incorporating this protein into biomarker panels and polygenic risk scores, which will improve the accuracy of personalized diagnostics.